Golden
CD19

CD19

Protein-coding gene in the species homo sapiens

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









News

Title
Author
Date
Publisher
Description
May 16, 2019
WebWire
Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity , , , , , , • Primary analysis of L-MIND trial of tafasitamab (MOR208) plus lenalidomide in relapsed or refractory (r/r) DLBCL confirms overall strong data reported previously from this trial, , • Objective response rate (ORR) of 60%, complete response (CR) rate of 43%, , • Median progression-free survival (mPFS) of 12.1 months with a median follow-up of...
Research and Markets
Invalid Date
www.prnewswire.com:443
DUBLIN, Feb. 14, 2019 /PRNewswire/ -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to...